Evaluation of the clinical significance of long non-coding RNA MALAT1 genetic variants in human lung adenocarcinoma

• Published in: Aging (Albany, NY.) NY.), 2024-03, Vol.16 (6), p.5740-5750
• Main Authors: Lin, Shu-Hui, Lu, Jeng-Wei, Hsieh, Wang-Ting, Chou, Ying-Erh, Su, Tzu-Cheng, Tsai, Tun-Jen, Tsai, Yun-Jung, Yang, Po-Jen, Yang, Shun-Fa
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - genetics; Clinical Relevance; ErbB Receptors - genetics; Genetic Predisposition to Disease; Humans; Lung; Lung Neoplasms - genetics; Polymorphism, Single Nucleotide; Research Paper; RNA, Long Noncoding - genetics
• ISSN: 1945-4589; 1945-4589
• DOI: 10.18632/aging.205675

Lung adenocarcinoma (LUAD) is the most frequent histological subtype of lung cancer, which is the most common malignant tumor and the main cause of cancer-related mortality globally. Recent reports revealed that long non-coding RNA (lncRNA) of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) plays a crucial role in tumorigenesis and metastasis development in lung cancer. However, the contribution of genetic variants to the development of LUAD is unclear, especially in epidermal growth factor receptor (EGFR) mutation status. In this study, 272 LADC patients with different EGFR status were recruited to dissect the allelic discrimination of the polymorphisms at rs3200401, rs619586, and rs1194338. The findings of the study showed that polymorphisms rs3200401, rs619586, and rs1194338 were not associated to LUAD susceptibility; however, rs3200401 polymorphisms was significantly correlated to EGFR wild-type status and tumor stages in LUAD patients in dominant model (p=0.016). Further analyses using the datasets from The Cancer Genome Atlas (TCGA) revealed that lower mRNA levels were associated with the advanced stage, and lymph node metastasis in LADC patients. In conclusion, our results showed that rs3200401 polymorphisms dramatically raised the probability of LUAD development.